Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid ...
Mit Blick auf die Neuausrichtung der Medikamentenpipeline von Bayer hatte Pharma-Chef Stefan Oelrich im letzten Januar ...
In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.
The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...
Bemdaneprocel will be studied in a sham-surgery controlled, double-blind trial that is expected to start in the first half of ...
Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...
Bayer used the Western Canadian Crop Production Show in Saskatoon this week to introduce Prairie farmers to its new FieldView ...